Open Access
ARTICLE
Neurodevelopmental outcomes at 2 and 4 years in children with congenital heart disease
1 Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin
2 Herma Heart Institute, Children’s Hospital of Wisconsin, Milwaukee, Wisconsin
* Corresponding Author: Cheryl Brosig, Medical College of Wisconsin, Department of Pediatrics, 8701 Watertown Plank Road, Milwaukee, WI 53226. Email:
Congenital Heart Disease 2018, 13(5), 700-705. https://doi.org/10.1111/chd.12632
Abstract
Background and Objectives: Children with congenital heart disease (CHD) are at risk for neurodevelopmental (ND) delays. The purpose of this study is to compare the ND testing results of children with CHD at 2 and 4 years of age and determine if rates of ND delays change over time.Methods: Children with CHD completed the Bayley Scales of Infant Development‐III (BSID‐III) at 2 years of age, and standardized neuropsychological measures at 4 years. Scores were compared with test norms and were classified as: average (within one SD of test mean); at risk (1‐2 SDs from the test mean); and delayed (>2 SD from test mean). Pearson correlations and McNemar’s exact tests were performed to deter‐ mine the relationship between test scores at the two times of assessment.
Results: Sixty‐four patients completed evaluations at 24 ± 3 months of age and 4 years of age. BSID‐III cognitive and fine motor scores were correlated with pre‐ school IQ and fine motor scores, r = .75 to .87, P < .0001. Agreement in score catego‐ ries was 79% for cognitive and 61% for fine motor. More patients had at risk or delayed scores at age 4 vs age 2 (P ≤ .01).
Conclusion(s): Despite significant correlations between 2‐ and 4‐year‐old test scores, many patients who scored in the average range at age 2 showed deficits at age 4. BSID‐III scores at age 2 may underestimate delays. Therefore, longitudinal ND as‐ sessment is recommended.
Keywords
Cite This Article
Brosig, C. L., Bear, L., Allen, S., Simpson, P., Zhang, L. et al. (2018). Neurodevelopmental outcomes at 2 and 4 years in children with congenital heart disease. Congenital Heart Disease, 13(5), 700–705.